NICE Technology Appraisal 607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
The production of this Guidelines card has been commissioned by Bayer plc. Bayer plc has reviewed the card for technical accuracy and regulatory compliance and supplied the prescribing information.
The production of this Guidelines card has been commissioned by Bayer plc. Bayer plc has reviewed this card for technical accuracy and regulatory compliance. The SMC has reviewed this card for technical accuracy and permission request only. The SMC were not involved in the production of this card.
Non-vitamin K oral anticoagulant options for patients with non-valvular atrial fibrillation and renal impairment
This NOAC dosing guide has been commissioned by Bayer, who also provided funding for its development. Bayer reviewed and approved the scope and pre-meeting documents, suggested the Chair and experts for the group, and put the dosing guide through full medical approval to ensure its compliance with appropriate regulations.
Related Guidelines in Practice articles
Dr Alan Begg summarises recommendations in SIGN’s latest guidance on cardiac arrhythmias that are relevant to primary care and highlights some major advances in treatment
Dr Dipankar Dutta discusses some important aspects of mechanical thrombectomy and implications for the NHS and primary care clinicians and commissioners
Dr Alan Begg compares SIGN and NICE recommendations on the diagnosis, assessment, and treatment of stable angina
Dr Sinead Clarke and Dr Nicola Harker provide top tips on mitigating the impact of cancer treatment on cardiovascular health
Professor Jonathan Mant summarises top tips for patients and practitioners on stroke risk assessment and reduction